R1	Has_qualifier Arg1:T2 Arg2:T3	
R2	Has_qualifier Arg1:T2 Arg2:T4	
R3	Has_qualifier Arg1:T2 Arg2:T1	
R4	Has_value Arg1:T5 Arg2:T7	
R5	AND Arg1:T6 Arg2:T5	
R6	Has_index Arg1:T10 Arg2:T11	
*	OR T8 T9
R7	Has_qualifier Arg1:T6 Arg2:T8	
R8	Has_temporal Arg1:T6 Arg2:T10	
R9	Has_multiplier Arg1:T14 Arg2:T13	
R10	Has_value Arg1:T15 Arg2:T17	
R11	AND Arg1:T16 Arg2:T15	
R12	AND Arg1:T18 Arg2:T19	
R13	Has_value Arg1:T19 Arg2:T20	
*	OR T21 T22
R14	Has_value Arg1:T23 Arg2:T24	
R15	Has_value Arg1:T25 Arg2:T26	
R16	Has_temporal Arg1:T27 Arg2:T28	
R17	Has_value Arg1:T32 Arg2:T33	
R18	Has_value Arg1:T34 Arg2:T35	
R19	Has_value Arg1:T30 Arg2:T31	
R20	Subsumes Arg1:T29 Arg2:T30	
R21	Has_value Arg1:T38 Arg2:T39	
R22	Has_value Arg1:T41 Arg2:T42	
R23	Has_value Arg1:T40 Arg2:T42	
R24	Has_value Arg1:T43 Arg2:T44	
R25	Has_value Arg1:T46 Arg2:T47	
R26	Has_value Arg1:T48 Arg2:T49	
*	OR T46 T48
R27	Has_value Arg1:T50 Arg2:T51	
R28	Has_negation Arg1:T53 Arg2:T52	
R29	Subsumes Arg1:T45 Arg2:T46	
R30	Subsumes Arg1:T37 Arg2:T38	
R31	Has_negation Arg1:T56 Arg2:T57	
*	OR T60 T59
R32	Has_qualifier Arg1:T61 Arg2:T60	
R33	AND Arg1:T61 Arg2:T58	
*	OR T56 T61
R34	Has_temporal Arg1:T61 Arg2:T63	
R35	Has_temporal Arg1:T58 Arg2:T64	
R36	Subsumes Arg1:T29 Arg2:T32	
R37	Subsumes Arg1:T29 Arg2:T34	
R38	Subsumes Arg1:T37 Arg2:T40	
R39	Subsumes Arg1:T37 Arg2:T41	
R40	Subsumes Arg1:T37 Arg2:T43	
T1	Qualifier 3 27	histologically confirmed
T2	Condition 88 114	non-small cell lung cancer
T3	Qualifier 129 143	wild-type EGFR
T4	Qualifier 148 160	ALK-negative
T5	Measurement 178 203	IASLC2009 new TNM staging
T6	Condition 207 218	lung cancer
T7	Value 219 246	stage <U+2162>B or <U+2163>
T8	Qualifier 259 268	untreated
T9	Qualifier 272 280	relapsed
T10	Temporal 281 318	after 1 year of lung cancer resection
T11	Reference_point 297 318	lung cancer resection
T13	Multiplier 328 340	at least one
T14	Condition 341 358	evaluable lesions
T15	Measurement 437 453	longest diameter
T16	Procedure 459 468	spiral CT
T17	Value 469 482	at least 10mm
T18	Procedure 488 498	regular CT
T19	Measurement 499 515	longest diameter
T20	Value 516 529	at least 20mm
T21	Person 535 539	Male
T22	Person 543 549	female
T23	Person 551 555	aged
T24	Value 556 570	18 to 75 years
T25	Measurement 575 582	ECOG PS
T26	Value 583 589	0 or 1
T27	Observation 594 611	expected survival
T28	Temporal 612 629	at least 3 months
T29	Condition 634 665	adequate hematological function
T30	Measurement 667 698	absolute neutrophil count (ANC)
T31	Value 699 716	at least 2×10^9/L
T32	Measurement 721 735	platelet count
T33	Value 736 755	at least 100×10^9/L
T34	Measurement 760 770	hemoglobin
T35	Value 771 786	at least 9 g/dL
T37	Condition 791 814	adequate liver function
T38	Measurement 816 831	total bilirubin
T39	Value 832 869	less than upper limit of normal (ULN)
T40	Measurement 871 874	AST
T41	Measurement 879 882	ALT
T42	Value 883 930	less than 2.5 times upper limit of normal (ULN)
T43	Measurement 932 952	alkaline phosphatase
T44	Value 953 1002	less than 5 times the upper limit of normal (ULN)
T45	Condition 1007 1030	adequate renal function
T46	Measurement 1032 1048	serum creatinine
T47	Value 1049 1086	less than upper limit of normal (ULN)
T48	Measurement 1090 1121	calculated creatinine clearance
T49	Value 1122 1140	at least 60 mL/min
T50	Measurement 1146 1149	ECG
T51	Value 1153 1159	normal
T52	Negation 1170 1172	no
T53	Condition 1173 1203	non-healing wounds on the body
T56	Drug 1245 1261	anticancer drugs
T57	Negation 1213 1225	not received
T58	Condition 1297 1318	non-metastatic tumors
T59	Qualifier 1331 1342	neoadjuvant
T60	Qualifier 1319 1327	adjuvant
T61	Procedure 1343 1355	chemotherapy
T63	Temporal 1399 1423	ended more than 6 months
T64	Temporal 1288 1296	previous
T65	Non-representable 1429 1561	have conducted previous surgery patients required to study treatment was started more than four weeks, and the patient had recovered
T66	Pregnancy_considerations 1567 1904	have an intact uterus in women prior to enrollment in the study must have a negative pregnancy test result (unless it is already 24 months of amenorrhea) within 28 days. If the pregnancy test from the first administration more than seven days, urine pregnancy test is required for authentication (less than 7 days before the first dose);
T67	Non-query-able 2032 2056	signed informed consent.
T68	Non-representable 1909 2027	previous to biological agents, particularly E.coli genetically engineered products without serious allergic reactions;
T69	Line 2028 2056	15) signed informed consent.
T70	Line 1905 2027	14) previous to biological agents, particularly E.coli genetically engineered products without serious allergic reactions;
T71	Line 1567 1904	have an intact uterus in women prior to enrollment in the study must have a negative pregnancy test result (unless it is already 24 months of amenorrhea) within 28 days. If the pregnancy test from the first administration more than seven days, urine pregnancy test is required for authentication (less than 7 days before the first dose);
T72	Line 1425 1562	12) have conducted previous surgery patients required to study treatment was started more than four weeks, and the patient had recovered;
T73	Line 1205 1423	11) had not received previous treatment anticancer drugs, or had only received for previous non-metastatic tumors adjuvant or neoadjuvant chemotherapy, but when you start to study treatment has ended more than 6 months
T74	Line 1146 1204	ECG is normal, there is no non-healing wounds on the body;
T75	Line 1007 1141	adequate renal function: serum creatinine less than upper limit of normal (ULN) or calculated creatinine clearance at least 60 mL/min;
T76	Line 791 1002	adequate liver function: total bilirubin less than upper limit of normal (ULN); AST and ALT less than 2.5 times upper limit of normal (ULN); alkaline phosphatase less than 5 times the upper limit of normal (ULN)
T77	Line 634 786	adequate hematological function: absolute neutrophil count (ANC) at least 2×10^9/L and platelet count at least 100×10^9/L and hemoglobin at least 9 g/dL
T78	Line 594 630	expected survival at least 3 months;
T79	Line 535 589	Male or female, aged 18 to 75 years; 5) ECOG PS 0 or 1
T80	Line 323 530	have at least one evaluable lesions,according to version 1.1 of the standard in accordance with a judgment RECIST(longest diameter on a spiral CT at least 10mm,on a regular CT longest diameter at least 20mm)
T81	Line 165 318	According to IASLC2009 new TNM staging of lung cancer stage <U+2162>B or <U+2163>, previously untreated or relapsed after 1 year of lung cancer resection
T82	Line 3 161	histologically confirmed (patients not receiving a single sputum cytology diagnosis) non-small cell lung cancer patients,with wild-type EGFR and ALK-negative;
